BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35748165)

  • 1. Remediating Desmoplasia with EGFR-Targeted Photoactivable Multi-Inhibitor Liposomes Doubles Overall Survival in Pancreatic Cancer.
    Obaid G; Bano S; Thomsen H; Callaghan S; Shah N; Swain JWR; Jin W; Ding X; Cameron CG; McFarland SA; Wu J; Vangel M; Stoilova-McPhie S; Zhao J; Mino-Kenudson M; Lin C; Hasan T
    Adv Sci (Weinh); 2022 Aug; 9(24):e2104594. PubMed ID: 35748165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunofluorescence profiling of collagen subtypes is a predictor of treatment outcomes in pancreatic cancer.
    Obaid G; Eroy M; Zhao J; Bano S; Mino-Kenudson M; Hasan T
    J Photochem Photobiol B; 2024 Jan; 250():112811. PubMed ID: 38000171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impacting Pancreatic Cancer Therapy in Heterotypic
    Obaid G; Bano S; Mallidi S; Broekgaarden M; Kuriakose J; Silber Z; Bulin AL; Wang Y; Mai Z; Jin W; Simeone D; Hasan T
    Nano Lett; 2019 Nov; 19(11):7573-7587. PubMed ID: 31518145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photoimmunotherapy Retains Its Anti-Tumor Efficacy with Increasing Stromal Content in Heterotypic Pancreatic Cancer Spheroids.
    Saad MA; Zhung W; Stanley ME; Formica S; Grimaldo-Garcia S; Obaid G; Hasan T
    Mol Pharm; 2022 Jul; 19(7):2549-2563. PubMed ID: 35583476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minocycline and photodynamic priming significantly improve chemotherapy efficacy in heterotypic spheroids of pancreatic ductal adenocarcinoma.
    Bano S; Alburquerque JQ; Roberts HJ; Pang S; Huang HC; Hasan T
    J Photochem Photobiol B; 2024 Jun; 255():112910. PubMed ID: 38663337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 Immune Checkpoint Targeted Photoactivable Liposomes (iTPALs) Prime the Stroma of Pancreatic Tumors and Promote Self-Delivery.
    Bhandari C; Moffat A; Shah N; Khan A; Quaye M; Fakhry J; Soma S; Nguyen A; Eroy M; Malkoochi A; Brekken R; Hasan T; Ferruzzi J; Obaid G
    Adv Healthc Mater; 2024 Feb; ():e2304340. PubMed ID: 38324463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting.
    Liang BJ; Pigula M; Baglo Y; Najafali D; Hasan T; Huang HC
    J Nanobiotechnology; 2020 Jan; 18(1):1. PubMed ID: 31898555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models.
    Hong E; Park S; Ooshima A; Hong CP; Park J; Heo JS; Lee S; An H; Kang JM; Park SH; Park JO; Kim SJ
    Sci Rep; 2020 Feb; 10(1):2935. PubMed ID: 32076068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
    Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
    Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic cytotoxicity and co-autophagy inhibition in pancreatic tumor cells and cancer-associated fibroblasts by dual functional peptide-modified liposomes.
    Chen X; Yu Q; Liu Y; Sheng Q; Shi K; Wang Y; Li M; Zhang Z; He Q
    Acta Biomater; 2019 Nov; 99():339-349. PubMed ID: 31499197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model.
    Wang J; Chan DKW; Sen A; Ma WW; Straubinger RM
    Mol Cancer Ther; 2019 Nov; 18(11):2074-2084. PubMed ID: 31363010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
    Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
    BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
    Ur Rehman SS; Lim K; Wang-Gillam A
    Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
    Chiang NJ; Chang JY; Shan YS; Chen LT
    Expert Opin Pharmacother; 2016 Jul; 17(10):1413-20. PubMed ID: 27140876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells.
    Momeny M; Esmaeili F; Hamzehlou S; Yousefi H; Javadikooshesh S; Vahdatirad V; Alishahi Z; Mousavipak SH; Bashash D; Dehpour AR; Tavangar SM; Tavakkoly-Bazzaz J; Haddad P; Kordbacheh F; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Cell Oncol (Dordr); 2019 Aug; 42(4):491-504. PubMed ID: 31025257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience.
    Tossey JC; Reardon J; VanDeusen JB; Noonan AM; Porter K; Arango MJ
    Med Oncol; 2019 Sep; 36(10):87. PubMed ID: 31494781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
    Hubner RA; Cubillo A; Blanc JF; Melisi D; Von Hoff DD; Wang-Gillam A; Chen LT; Becker C; Mamlouk K; Belanger B; Yang Y; de Jong FA; Siveke JT
    Eur J Cancer; 2019 Jan; 106():24-33. PubMed ID: 30458340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages.
    Incio J; Suboj P; Chin SM; Vardam-Kaur T; Liu H; Hato T; Babykutty S; Chen I; Deshpande V; Jain RK; Fukumura D
    PLoS One; 2015; 10(12):e0141392. PubMed ID: 26641266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer.
    Smith CJ; Bekaii-Saab TS; Cook KD; Eiring RA; Halfdanarson TR; Hanna M; Jin Z; Jochum JA; Ma WW; Mitchell JL; Pitot HC; Jatoi A
    Pancreatology; 2021 Mar; 21(2):379-383. PubMed ID: 33468394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer.
    Huang HC; Mallidi S; Liu J; Chiang CT; Mai Z; Goldschmidt R; Ebrahim-Zadeh N; Rizvi I; Hasan T
    Cancer Res; 2016 Mar; 76(5):1066-77. PubMed ID: 26719532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.